S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Seven millionaires secretly enable market shock? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
66,000% upside on tiny biotech? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Seven millionaires secretly enable market shock? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
66,000% upside on tiny biotech? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Seven millionaires secretly enable market shock? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
66,000% upside on tiny biotech? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Seven millionaires secretly enable market shock? (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
66,000% upside on tiny biotech? (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
66,000% upside on tiny biotech? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NYSE:ENZ

Enzo Biochem (ENZ) Stock Forecast, Price & News

$1.38
+0.01 (+0.73%)
(As of 09/25/2023 ET)
Compare
Today's Range
$1.37
$1.45
50-Day Range
$1.30
$1.64
52-Week Range
$1.00
$2.74
Volume
59,402 shs
Average Volume
450,087 shs
Market Capitalization
$68.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ENZ stock logo

About Enzo Biochem (NYSE:ENZ) Stock

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in Farmingdale, New York.

ENZ Price History

ENZ Stock News Headlines

Comparing Enzo Biochem (NYSE:ENZ) & BioNexus Gene Lab (NASDAQ:BGLC)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Enzo Biochem CEO Hamid Erfanian Resigns After Two Years
Enzo Biochem (NYSE: ENZ)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Enzo Biochem cuts price for labs assets to Labcorp
Short Volatility Alert: Enzo Biochem Inc
Enzo Biochem reports Q3 results
See More Headlines
Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Company Calendar

Last Earnings
10/15/2019
Today
9/25/2023
Next Earnings (Estimated)
10/13/2023
Fiscal Year End
7/31/2024

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
465
Year Founded
1976

Profitability

Net Income
$-18,260,000.00
Pretax Margin
-64.19%

Debt

Sales & Book Value

Annual Sales
$107.07 million
Book Value
$1.12 per share

Miscellaneous

Free Float
41,965,000
Market Cap
$70.02 million
Optionable
Optionable
Beta
0.95

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Hamid Erfanian (Age 53)
    CEO & Director
    Comp: $929.46k
  • Dr. Elazar Rabbani Ph.D. (Age 80)
    Co-Founder & Director
    Comp: $3.23M
  • Ms. Kara Cannon (Age 54)
    Chief Operating Officer
    Comp: $474.28k
  • Ms. Patricia Eckert CPA (Age 46)
    Interim Chief Financial Officer
  • Mr. Matthew Kupferberg (Age 57)
    Gen. Counsel & Sec.













ENZ Stock - Frequently Asked Questions

How have ENZ shares performed in 2023?

Enzo Biochem's stock was trading at $1.43 on January 1st, 2023. Since then, ENZ shares have decreased by 1.4% and is now trading at $1.41.
View the best growth stocks for 2023 here
.

Are investors shorting Enzo Biochem?

Enzo Biochem saw a increase in short interest in the month of August. As of August 15th, there was short interest totaling 1,530,000 shares, an increase of 5.5% from the July 31st total of 1,450,000 shares. Based on an average daily volume of 320,400 shares, the short-interest ratio is currently 4.8 days. Currently, 4.0% of the company's shares are sold short.
View Enzo Biochem's Short Interest
.

When is Enzo Biochem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, October 13th 2023.
View our ENZ earnings forecast
.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) released its quarterly earnings data on Tuesday, October, 15th. The medical research company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. The medical research company had revenue of $20.92 million for the quarter. Enzo Biochem had a negative net margin of 64.19% and a negative trailing twelve-month return on equity of 116.13%.

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (5.45%), Dimensional Fund Advisors LP (2.55%), Potomac Capital Management Inc. (2.11%), BlackRock Inc. (2.01%), Roumell Asset Management LLC (1.37%) and Geode Capital Management LLC (0.68%). Insiders that own company stock include Bradley Louis Radoff, David Bench, Discovery Fund Lp Harbert, Hamid Erfanian, James G Wolf and Kara Cannon.
View institutional ownership trends
.

How do I buy shares of Enzo Biochem?

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $1.41.

How much money does Enzo Biochem make?

Enzo Biochem (NYSE:ENZ) has a market capitalization of $70.02 million and generates $107.07 million in revenue each year. The medical research company earns $-18,260,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.

How many employees does Enzo Biochem have?

The company employs 465 workers across the globe.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The official website for the company is www.enzo.com. The medical research company can be reached via phone at (212) 583-0100, via email at ir@enzo.com, or via fax at 212-679-7999.

This page (NYSE:ENZ) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -